Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KRRO
STRONG SELLKorro Bio, Inc. · Healthcare · United States · $153M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Korro Bio, Inc. is a biotechnology company pioneering the development of RNA editing therapies for serious diseases, utilizing its proprietary OPERA™ platform. The company operates at the cutting edge of genetic medicine, aiming to precisely modify RNA to create therapeutic proteins without altering the underlying DNA. Korro Bio is a preclinical-stage biopharmaceutical company focused on a novel and potentially transformative therapeutic modality, representing a high-risk, high-reward investment in the gene editing space.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 2.3M | 6.4M | 181.5% | 3.8M | 0.5M | 0.2M | -81.4% |
| EPS | -2.74 | -7.25 | -53.08 | -9.37 | -12.48 | — | -11.01 | — | — | — |
| Shares | — | 8.0M | 8.0M | 9.4M | 9.4M | +17.7% | — | — | — | — |
| Debt | — | 3.1M | 33.2M | 44.8M | 43.5M | 140.4% | 42.9M | — | — | — |
| Equity | — | -99.0M | 169.9M | 160.4M | 51.4M | -45.0% | — | — | — | — |
| Op CF | — | -53.6M | -67.3M | -60.1M | -78.6M | — | -70.2M | — | — | — |
| Inv CF | — | 11.1M | 11.2M | -123.3M | 44.0M | — | — | — | — | — |
| Fin CF | — | 18.0K | 187.8M | 69.4M | 0.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KRRO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KRRO | Korro Bio, Inc.(you) | $153M | 12 | STRONG SELL |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $157M | 12 | STRONG SELL |
| ABOS | Acumen Pharmaceuticals, Inc. | $154M | 14 | STRONG SELL |
| PYXS | Pyxis Oncology, Inc. | $165M | 13 | STRONG SELL |
| CNTN | Canton Strategic Holdings, Inc. | $150M | 14 | STRONG SELL |
| 0HIY.L | Atara Biotherapeutics, Inc. | $161M | 10 | STRONG SELL |
| CDXS | Codexis, Inc. | $135M | 12 | STRONG SELL |
| ARCT | Arcturus Therapeutics Holdings Inc. | $157M | 15 | STRONG SELL |
| UNCY | Unicycive Therapeutics, Inc. | $148M | 15 | STRONG SELL |
| IVVD | Invivyd, Inc. | $180M | 12 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%